Sander Brooks (S Brooks)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 4

Top Topics

Placebo Controlled

Major Depressive Disorder

Top Venues

Journal of psychopharmacology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Sander Brooks, Rob G J A Zuiker, C Bleys, D Ziagkos, J A Moyer, L van Nueten, P Bonaventure, W C Drevets, Jma van Gerven, G Salvadore, G E Jacobs
Pharmacological characterization of the selective orexin-1 receptor antagonist JNJ-61393215 in healthy volunteers. Journal of psychopharmacology (Oxford, England) (2023)
Benjamin Berger, Sander Brooks, Rob G J A Zuiker, Muriel Richard, Clemens Muehlan, Jasper Dingemanse
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects. CNS drugs 34 (12) (2020)
Sander Brooks, Gabriël E Jacobs, Peter De Boer, Justine M Kent, Luc Van Nueten, Guido van Amerongen, Rob Zuiker, Iva Kezic, Remy Luthringer, Peter D van der Ark, Joop Ma van Gerven, Wayne Drevets
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. Journal of psychopharmacology (Oxford, England) 33 (2) (2019)
Clemens Muehlan, Margaux Boehler, Sander Brooks, Rob G J A Zuiker, Joop van Gerven, Jasper Dingemanse
Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. Journal of psychopharmacology (Oxford, England) 34 (3) (2019)